Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
36 Results for "
aldo-keto
" in MedChemExpress (MCE) Product Catalog:
Products (36)
36 Results for "aldo-keto" in MCE Product Catalog:
3
3 Cited Publications
Research Areas:
S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
1
1 Cited Publications
Cat. No.: HY-P7604
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: AKR1C3; aldo-keto Reductase Family 1, Member C3 (3-Alpha Hydroxysteroid Dehydrogenase, Type II), Isoform CRA_a; Prev. HSD17B5; Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase; PGFS; Type IIb 3-Alpha Hydroxysteroid Dehydrogenase; Prostaglandin F Synthase; 3-Alpha-Hydroxysteroid Dehydrogenase Type 2; KIAA0119; 17-Beta-Hydroxysteroid Dehydrogenase Type 5; HAKRB; Hydroxysteroid (17-Beta) Dehydrogenase 5; DDX; Dihydrodiol Dehydrogenase Type I; 3-Alpha Hydroxysteroid Dehydrogenase, Type II; Indanol Dehydrogenase; Testosterone 17-Beta-Dehydrogenase 5; 3-Alpha-HSD Type 2; Chlordecone Reductase Homolog HAKRb; 17-Beta-HSD 5; Dihydrodiol Dehydrogenase X; HluPGFS; Dihydrodiol Dehydrogenase 3; HAKRe; 3-Alpha-HSD Type II, Brain; DD-3; HA1753; DDH1; DD3; aldo-keto Reductase Family 1 Member C3; aldo-keto Reductase Family 1, Member C3 (3-Alpha Hydroxysteroid Dehydrogenase, Type II)
Species:
Human
Source:
HEK293
Synonyms: OBI-3424; TH-3424; (R)-AST-3424
Research Areas:
(R)-Odafosfamide (OBI-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. (R)-Odafosfamide can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research .
Target:
Research Areas:
AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells .
Target:
Research Areas:
Obafistat is a potent aldo-keto reductase AKR1C3 inhibitor with an IC50 of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4) .
Research Areas:
AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research .
Research Areas:
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC50 value of 3.04 nM. S19-1035 can be used for the research of tumor .
Cat. No.: HY-176084
CAS No.: 2851993-77-4
Research Areas:
RJG-2051 is a selective covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 value of 13 nM. RJG-2051 interferes with the metabolic process of substrates such as androgens, estrogens, and prostaglandins by AKR1C3. RJG-2051 is promising for research of cancers .
Research Areas:
AKR1C3-IN-9 is a selective inhibitor of Aldo-keto Reductase 1C3 (AKR1C3) with an IC50 value of 8.92 nM. AKR1C3-IN-9 significantly reverses the Doxorubicin (HY-15142A) (DOX) resistance in a resistant breast cancer cell line .
Cat. No.: HY-116170
CAS No.: 1548116-54-6
SN34037 is a specific inhibitor of Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) with the ability to inhibit the cytotoxic activity of PR-104A. SN34037-sensitive coumberone reduction provides a rapid and specific assay for AKR1C3 activity. SN34037 inhibits the aerobic cytotoxicity of PR-104A in TF1 erythroleukemia cells with high AKR1C3 expression, but not in Nalm6 pre-B acute lymphoblastic leukemia cells with low AKR1C3 expression .
Cat. No.: HY-156701
CAS No.: 1428988-21-9
Target:
Research Areas:
BAY-1128688 is a selective, orally active aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 of 1.4 nM. BAY-1128688 inhibits OATP, BSEP, MRP4, NTCP, UGT1A1, MRP2, and MRP3. BAY-1128688 induces reactive oxygen species (ROS) production, inhibits the mitochondrial electron transport chain, and increases circulating androsterone, etiocholanolone, dihydrotestosterone, and serum bilirubin concentrations. BAY-1128688 alters bilirubin disposition, leading to elevated plasma bilirubin, independent of liver injury. BAY-1128688 can be used in research on endometriosis and polycystic ovary syndrome .
Cat. No.: HY-W010617
CAS No.: 822-67-3
Target:
Research Areas:
2-Cyclohexen-1-ol is a biochemical reagent. 2-Cyclohexen-1-ol is the oxidation substrate of mouse aldo-keto reductase AKR1C12, with a Km of 1080 μM and a Kcat of 13 min -1, showing low catalytic efficiency .
Cat. No.: HY-150646
CAS No.: 1580241-55-9
Research Areas:
S07-2009 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.20 μM .
Cat. No.: HY-150648
CAS No.: 1090816-80-0
Research Areas:
S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 of 0.16 μM. S07-2008 shows anticancer activities .
Cat. No.: HY-163323
CAS No.: 891075-67-5
Research Areas:
AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .
Cat. No.: HY-150650
CAS No.: 1197904-57-6
Research Areas:
S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance .
Research Areas:
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells .
Cat. No.: HY-150649
CAS No.: 1826337-40-9
Research Areas:
S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance .
Cat. No.: HY-P75521
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: AKR1B1; ALR2; Prev. ALDR1; Lii5-2 CTCL Tumor Antigen; aldose Reductase; Low Km aldose Reductase; AR; Aldehyde Reductase 1; aldo-keto Reductase Family 1 Member B1; ADR; Aldehyde Reductase; aldo-keto Reductase Family 1 Member B; aldo-keto Reductase Family 1
Species:
Human
Source:
E. coli
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
